A nasal inhaler for the inhalation of inhalable substances comprise: a canister having an interior reservoir containing pressurised inhalable substances including fluid; a metering valve including a metering chamber and a valve stem defining a communication path between the metering chamber and the interior reservoir, the communication path including an opening configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas located within the metering chamber is replaced with liquid from the interior reservoir.

A security tag can prohibit unauthorized usage of a device or product. The device may include an electronic nicotine delivery systems (“ENDS”) device, which may include aerosol delivery devices such as smoking articles that produce aerosol. The security tag can prevent usage until authorized. Attempts at usage without authorization can result in the device being unusable. The authorization may include identity confirmation or age verification.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Provided is a composition for treating and/or preventing cognitive impairment or dementia. The composition for treating and/or preventing cognitive impairment or dementia containing hydrogen gas, wherein the composition is used to allow the hydrogen gas to be inhaled by a subject. The concentration of the hydrogen gas to be inhaled is, for example, 0.5 to 18.3 vol %. The concentration of the hydrogen gas to be inhaled is, for example, 1 to 10 vol %. For example, the time of inhalation of the hydrogen gas is at least 10 minutes or longer per inhalation, and the frequency of inhalation of the hydrogen gas is once or more per day.

Disclosed here is an adenosine derivative prodrug that can have reverse transcriptase inhibitor activity in vivo. This disclosure is also directed to a pharmaceutical composition comprising the adenosine derivative that can be used for the treatment of HIV infection or RNA virus infection.

The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically, the liposomal composition is used for prevention, or early treatment, of pathogenic infection in the respiratory tract, preferably by nasal or pulmonary administration.

A foam inhalation device (874) for dispensing a foam to be inhaled by a user. The inhalation device (874) comprises a foam-generating component for generating the foam, an outlet (882) for dispensing the foam to the user, and a fluid flow path which fluidly communicates the foam-generating component with the outlet (882). The foam is generatable by the foam-generating component and flows to the outlet (882) via the fluid flow path to be inhaled by the user.

A non-crystallizing blend includes cannabidiol (CBD) and cannabidiolic acid (CBDA). A method of forming a non-crystallizing blend of CBD and CBDA includes obtaining a CBD isolate including at least 80% by weight CBD, obtaining a CBDA isolate including at least 80% by weight CBDA, and combining and mixing the CBD isolate and the CBDA. A method of treating a condition includes administering a therapeutically effective amount of a non-crystallizing blend of CBD and CBDA to a patient in need thereof.

Embodiments of the disclosure relate to dosage forms intended for smoking, vaporization and/or inhalation and to methods for the preparations thereof.

An inhaler (10) has a main body for accommodating a medicament reservoir (84), a canister fire system for moving a canister (50) to release a dose in response to air flow, a cap housing (12) for enclosing the canister fire system and canister within an interior chamber defined by the main body (14) and a cap housing, wherein a lock system (250) is provided for locking the cap housing on the main body.